Search clinical trials for: retigabine/ezogabine

Total 26 results

GlaxoSmithKline

Completed

Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects

Epilepsy

Taiwan
GlaxoSmithKline
Bausch Health Americas, Inc.

Terminated

Study in Pediatric Subjects With Epilepsy

Epilepsy

United States
GlaxoSmithKline
Bausch Health Americas, Inc.

Terminated

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Epilepsy

United States
University Hospital of Mont-Godinne
GlaxoSmithKline; Université Catholique de Louvain

Completed

Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study (CERETI)

Epilepsy

Belgium
GlaxoSmithKline

Completed

Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304

Epilepsy, Partial
GlaxoSmithKline

Withdrawn

Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

Epilepsy, Partial

Japan
Icahn School of Medicine at Mount Sinai

Completed

Study to Treat Major Depressive Disorder (MDD) With a New Medication

Depression | Major Depressive Disorder

United States
GlaxoSmithKline

Completed

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

Epilepsy

United States, Canada, Argentina, Brazil, Mexico
Xenon Pharmaceuticals Inc.

Terminated

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (EPIK)

Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Epilepsy | Epileptic Syndromes | Disease | Epilepsy; Seizure | Epilepsy in Children

United States, Spain, Australia, Belgium, Italy
GlaxoSmithKline

Completed

Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite

Epilepsy

United States
GlaxoSmithKline
Bausch Health Americas, Inc.

Terminated

Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures

Seizures

United States, Greece
GlaxoSmithKline

Terminated

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

Epilepsy

United States, France, Poland
GlaxoSmithKline

Terminated

Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097

Epilepsy

Spain, Australia, Russian Federation, Israel, Belgium, Hungary, France, Germany, Poland, South Africa, Ukraine, United Kingdom
GlaxoSmithKline

Terminated

Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures

Epilepsy

Thailand, Korea, Republic of, Singapore, Hong Kong, Taiwan, Malaysia, Philippines
Brian Wainger
Massachusetts General Hospital; GlaxoSmithKline; ALS Association; Harvard University

Completed

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

Amyotrophic Lateral Sclerosis

United States
Xenon Pharmaceuticals Inc.

Terminated

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE (EPIK-OLE)

Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Epilepsy | Epileptic Syndromes | Disease | Epilepsy; Seizure | Epilepsy in Children

United States, Australia, Belgium
GlaxoSmithKline

Completed

A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

Epilepsy

Thailand, Korea, Republic of, Malaysia
Bausch Health Americas, Inc.

Completed

Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

Postherpetic Neuralgia

United States, South Africa
GlaxoSmithKline

Completed

Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) (IR)

Epilepsy

Bulgaria, Thailand, Russian Federation, Belgium, Italy, Ukraine, France, Germany, Netherlands, Poland
GlaxoSmithKline
Bausch Health Americas, Inc.

Completed

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy (RESTORE1)

Seizures

United States, Canada, Argentina, Brazil, Mexico
GlaxoSmithKline

Completed

Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures (IR)

Epilepsy

Bulgaria, Belgium, Thailand, Denmark, Russian Federation, Italy, Spain, Ukraine, Netherlands, Germany, France, Poland
GlaxoSmithKline
Bausch Health Americas, Inc.

Completed

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy (RESTORE2)

Seizures

Spain, Australia, Israel, Ukraine, Belgium, United States, South Africa, Hungary, United Kingdom, France, Germany, Poland, Russian Federation
GlaxoSmithKline

Completed

An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed

Epilepsy

United States
The People's Hospital of Gaozhou

Recruiting

Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution

Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution in Improving Nutritional Status of Maintenance Peritoneal Dialysis Patients

China
GlaxoSmithKline

Completed

Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy

Epilepsy
James Murrough
National Institute of Mental Health (NIMH); Baylor College of Medicine

Completed

Study to Treat Major Depressive Disorder With a New Medication

Depressive Disorder | Anhedonia

United States

Search clinical trials for: retigabine/ezogabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations